# Matthew C Kiernan

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/1942385/publications.pdf

Version: 2024-02-01

| | | | |
|---|---|---|---|
| 434 papers | 24,550 citations | 6254 80 h-index | 11308 136 g-index |
| 445 all docs | 445 docs citations | 445 times ranked | 17915 citing authors |

| # | Article | IF | Citations |
|---|---|---|---|
| 1 | Amyotrophic lateral sclerosis. Lancet, The, 2011, 377, 942-955. | 13.7 | 2,182 |
| 2 | Chemotherapyâ€induced peripheral neurotoxicity: A critical analysis. Ca-A Cancer Journal for Clinicians, 2013, 63, 419-437. | 329.8 | 547 |
| 3 | Clinical diagnosis and management of amyotrophic lateral sclerosis. Nature Reviews Neurology, 2011, 7, 639-649. | 10.1 | 503 |
| 4 | Genome-wide association analyses identify new risk variants and the genetic architecture of amyotrophic lateral sclerosis. Nature Genetics, 2016, 48, 1043-1048. | 21.4 | 494 |
| 5 | Controversies and priorities in amyotrophic lateral sclerosis. Lancet Neurology, The, 2013, 12, 310-322. | 10.2 | 454 |
| 6 | Multiple measures of axonal excitability: A new approach in clinical testing. Muscle and Nerve, 2000, 23, 399-409. | 2.2 | 412 |
| 7 | Cortical hyperexcitability may precede the onset of familial amyotrophic lateral sclerosis. Brain, 2008, 131, 1540-1550. | 7.6 | 391 |
| 8 | Biomarkers in amyotrophic lateral sclerosis. Lancet Neurology, The, 2009, 8, 94-109. | 10.2 | 391 |
| 9 | Excitability of human axons. Clinical Neurophysiology, 2001, 112, 1575-1585. | 1.5 | 384 |
| 10 | Chronic inflammatory demyelinating polyradiculoneuropathy: from pathology to phenotype. Journal of Neurology, Neurosurgery and Psychiatry, 2015, 86, 973-985. | 1.9 | 320 |
| 11 | Strength-duration properties of human peripheral nerve. Brain, 1996, 119, 439-447. | 7.6 | 316 |
| 12 | Amyotrophic lateral sclerosis: moving towards a new classification system. Lancet Neurology, The, 2016, 15, 1182-1194. | 10.2 | 301 |
| 13 | The frontotemporal dementia-motor neuron disease continuum. Lancet, The, 2016, 388, 919-931. | 13.7 | 294 |
| 14 | Novel threshold tracking techniques suggest that cortical hyperexcitability is an early feature of motor neuron disease. Brain, 2006, 129, 2436-2446. | 7.6 | 284 |
| 15 | Motor Neuron dysfunction in frontotemporal dementia. Brain, 2011, 134, 2582-2594. | 7.6 | 271 |
| 16 | A proposal for new diagnostic criteria for ALS. Clinical Neurophysiology, 2020, 131, 1975-1978. | 1.5 | 268 |
| 17 | Common and rare variant association analyses in amyotrophic lateral sclerosis identify 15 risk loci with distinct genetic architectures and neuron-specific biology. Nature Genetics, 2021, 53, 1636-1648. | 21.4 | 223 |
| 18 | Transcranial magnetic stimulation and amyotrophic lateral sclerosis: pathophysiological insights. Journal of Neurology, Neurosurgery and Psychiatry, 2013, 84, 1161-1170. | 1.9 | 213 |

| # | Article | IF | Citations |
|---|---|---|---|
| 19 | FUS mutations in amyotrophic lateral sclerosis: clinical, pathological, neurophysiological and genetic analysis. Journal of Neurology, Neurosurgery and Psychiatry, 2010, 81, 639-645. | 1.9 | 205 |
| 20 | Oxaliplatin-induced neurotoxicity: changes in axonal excitability precede development of neuropathy. Brain, 2009, 132, 2712-2723. | 7.6 | 198 |
| 21 | Oxaliplatinâ€induced neurotoxicity and the development of neuropathy. Muscle and Nerve, 2005, 32, 51-60. | 2.2 | 194 |
| 22 | Activity-dependent hyperpolarization of human motor axons produced by natural activity. Journal of Physiology, 1998, 507, 919-925. | 2.9 | 191 |
| 23 | Advances in treating amyotrophic lateral sclerosis: insights from pathophysiological studies. Trends in Neurosciences, 2014, 37, 433-442. | 8.6 | 186 |
| 24 | Axonal excitability properties in amyotrophic lateral sclerosis. Clinical Neurophysiology, 2006, 117, 1458-1466. | 1.5 | 177 |
| 25 | TDP-43 proteinopathies: a new wave of neurodegenerative diseases. Journal of Neurology, Neurosurgery and Psychiatry, 2021, 92, 86-95. | 1.9 | 174 |
| 26 | Recent Developments in TSPO PET Imaging as A Biomarker of Neuroinflammation in Neurodegenerative Disorders. International Journal of Molecular Sciences, 2019, 20, 3161. | 4.1 | 173 |
| 27 | Long-Term Neuropathy After Oxaliplatin Treatment: Challenging the Dictum of Reversibility. Oncologist, 2011, 16, 708-716. | 3.7 | 171 |
| 28 | Consensus for experimental design in electromyography (CEDE) project: Amplitude normalization matrix. Journal of Electromyography and Kinesiology, 2020, 53, 102438. | 1.7 | 170 |
| 29 | Evidence for axonal membrane hyperpolarization in multifocal motor neuropathy with conduction block. Brain, 2002, 125, 664-675. | 7.6 | 169 |
| 30 | Grey and White Matter Changes across the Amyotrophic Lateral Sclerosis-Frontotemporal Dementia Continuum. PLoS ONE, 2012, 7, e43993. | 2.5 | 168 |
| 31 | How common are behavioural changes in amyotrophic lateral sclerosis?. Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders, 2011, 12, 45-51. | 2.1 | 165 |
| 32 | Pathophysiological and diagnostic implications of cortical dysfunction in ALS. Nature Reviews Neurology, 2016, 12, 651-661. | 10.1 | 165 |
| 33 | Sensitivity and specificity of threshold tracking transcranial magnetic stimulation for diagnosis of amyotrophic lateral sclerosis: a prospective study. Lancet Neurology, The, 2015, 14, 478-484. | 10.2 | 164 |
| 34 | Assessment of cortical excitability using threshold tracking techniques. Muscle and Nerve, 2006, 33, 477-486. | 2.2 | 162 |
| 35 | Acute tetrodotoxin-induced neurotoxicity after ingestion of puffer fish. Annals of Neurology, 2005, 57, 339-348. | 5.3 | 159 |
| 36 | Neuroinflammation in frontotemporal dementia. Nature Reviews Neurology, 2019, 15, 540-555. | 10.1 | 159 |

| # | Article | IF | Citations |
|---|---|---|---|
| 37 | Emerging therapies and challenges in spinal muscular atrophy. Annals of Neurology, 2017, 81, 355-368. | 5.3 | 157 |
| 38 | Acute Abnormalities of Sensory Nerve Function Associated With Oxaliplatin-Induced Neurotoxicity. Journal of Clinical Oncology, 2009, 27, 1243-1249. | 1.6 | 153 |
| 39 | Cortical influences drive amyotrophic lateral sclerosis. Journal of Neurology, Neurosurgery and Psychiatry, 2017, 88, 917-924. | 1.9 | 152 |
| 40 | Improving clinical trial outcomes in amyotrophic lateral sclerosis. Nature Reviews Neurology, 2021, 17, 104-118. | 10.1 | 152 |
| 41 | Kidneyâ€“brain crosstalk in the acute and chronic setting. Nature Reviews Nephrology, 2015, 11, 707-719. | 9.6 | 151 |
| 42 | Axonal ion channels from bench to bedside: A translational neuroscience perspective. Progress in Neurobiology, 2009, 89, 288-313. | 5.7 | 144 |
| 43 | Frontotemporal Dementia Associated With theC9ORF72Mutation. JAMA Neurology, 2014, 71, 331. | 9.0 | 144 |
| 44 | Clinical evaluation of excitability measures in sensory nerve. Muscle and Nerve, 2001, 24, 883-892. | 2.2 | 141 |
| 45 | Cortical hyperexcitability precedes lower motor neuron dysfunction in ALS. Clinical Neurophysiology, 2015, 126, 803-809. | 1.5 | 140 |
| 46 | Quantifying disease progression in amyotrophic lateral sclerosis. Annals of Neurology, 2014, 76, 643-657. | 5.3 | 133 |
| 47 | Emerging insights into the complex genetics and pathophysiology of amyotrophic lateral sclerosis. Lancet Neurology, The, 2022, 21, 465-479. | 10.2 | 130 |
| 48 | Differences in activity-dependent hyperpolarization in human sensory and motor axons. Journal of Physiology, 2004, 558, 341-349. | 2.9 | 129 |
| 49 | Amyotrophic lateral sclerosis and frontotemporal dementia: A behavioural and cognitive continuum. Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders, 2012, 13, 102-109. | 2.1 | 124 |
| 50 | Recent advances in the diagnosis and prognosis of amyotrophic lateral sclerosis. Lancet Neurology, The, 2022, 21, 480-493. | 10.2 | 124 |
| 51 | Riluzole exerts central and peripheral modulating effects in amyotrophic lateral sclerosis. Brain, 2013, 136, 1361-1370. | 7.6 | 123 |
| 52 | Nerve excitability changes in chronic renal failure indicate membrane depolarization due to hyperkalaemia. Brain, 2002, 125, 1366-1378. | 7.6 | 122 |
| 53 | Cortical excitability distinguishes ALS from mimic disorders. Clinical Neurophysiology, 2011, 122, 1860-1866. | 1.5 | 122 |
| 54 | Does interneuronal dysfunction contribute to neurodegeneration in amyotrophic lateral sclerosis?. Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders, 2012, 13, 245-250. | 2.1 | 121 |

| # | Article | IF | Citations |
|---|---|---|---|
| 55 | Amyotrophic lateral sclerosis and frontotemporal dementia: distinct and overlapping changes in eating behaviour and metabolism. Lancet Neurology, The, 2016, 15, 332-342. | 10.2 | 120 |
| 56 | Primary lateral sclerosis: consensus diagnostic criteria. Journal of Neurology, Neurosurgery and Psychiatry, 2020, 91, 373-377. | 1.9 | 118 |
| 57 | Altered nerve excitability properties in established diabetic neuropathy. Brain, 2005, 128, 1178-1187. | 7.6 | 114 |
| 58 | Retiring the term FTDP-17 as MAPT mutations are genetic forms of sporadic frontotemporal tauopathies. Brain, 2018, 141, 521-534. | 7.6 | 114 |
| 59 | The Puzzling Case of Hyperexcitability in Amyotrophic Lateral Sclerosis. Journal of Clinical Neurology | | |

| # | Article | IF | Citations |
|---|---|---|---|
| 73 | Impact of oxaliplatin-induced neuropathy: a patient perspective. Supportive Care in Cancer, 2012, 20, 2959-2967. | 2.2 | 93 |
| 74 | Differentiating lower motor neuron syndromes. Journal of Neurology, Neurosurgery and Psychiatry, 2017, 88, 474-483. | 1.9 | 93 |
| 75 | Pathophysiological insights into ALS with C9ORF72 expansions. Journal of Neurology, Neurosurgery and Psychiatry, 2013, 84, 931-935. | 1.9 | 89 |
| 76 | Transcranial Magnetic Stimulation for the Assessment of Neurodegenerative Disease. Neurotherapeutics, 2017, 14, 91-106. | 4.4 | 89 |
| 77 | Activity-dependent excitability changes suggest Na+/K+ pump dysfunction in diabetic neuropathy. Brain, 2008, 131, 1209-1216. | 7.6 | 87 |
| 78 | Assessment of the upper motor neuron in amyotrophic lateral sclerosis. Clinical Neurophysiology, 2016, 127, 2643-2660. | 1.5 | 87 |
| 79 | Upregulation of persistent sodium conductances in familial ALS. Journal of Neurology, Neurosurgery and Psychiatry, 2010, 81, 222-227. | 1.9 | 86 |
| 80 | Diagnostic contribution and therapeutic perspectives of transcranial magnetic stimulation in dementia. Clinical Neurophysiology, 2021, 132, 2568-2607. | 1.5 | 85 |
| 81 | Oxaliplatin and Axonal Na+ Channel Function In vivo. Clinical Cancer Research, 2006, 12, 4481-4484. | 7.0 | 82 |
| 82 | Cerebellar Integrity in the Amyotrophic Lateral Sclerosis - Frontotemporal Dementia Continuum. PLoS ONE, 2014, 9, e105632. | 2.5 | 79 |
| 83 | Effect of Ezogabine on Cortical and Spinal Motor Neuron Excitability in Amyotrophic Lateral Sclerosis. JAMA Neurology, 2021, 78, 186. | 9.0 | 79 |
| 84 | Motor cortical function determines prognosis in sporadic ALS. Neurology, 2016, 87, 513-520. | 1.1 | 76 |
| 85 | Fasciculation in amyotrophic lateral sclerosis: origin and pathophysiological relevance. Journal of Neurology, Neurosurgery and Psychiatry, 2017, 88, 773-779. | 1.9 | 76 |
| 86 | Nerve function and dysfunction in acute intermittent porphyria. Brain, 2008, 131, 2510-2519. | 7.6 | 75 |
| 87 | Cortical Dysfunction Underlies the Development of the Split-Hand in Amyotrophic Lateral Sclerosis. PLoS ONE, 2014, 9, e87124. | 2.5 | 75 |
| 88 | Psychiatric disorders in C9orf72 kindreds. Neurology, 2018, 91, e1498-e1507. | 1.1 | 75 |
| 89 | Assessment of disease progression in motor neuron disease. Lancet Neurology, The, 2005, 4, 229-238. | 10.2 | 74 |
| 90 | Cortical excitability testing distinguishes Kennedyâ€™s disease from amyotrophic lateral sclerosis. Clinical Neurophysiology, 2008, 119, 1088-1096. | 1.5 | 74 |

| # | Article | IF | Citations |
|---|---|---|---|
| 91 | Cortical Function in Asymptomatic Carriers and Patients WithC9orf72Amyotrophic Lateral Sclerosis. JAMA Neurology, 2015, 72, 1268. | 9.0 | 74 |
| 92 | Awaji criteria improves the diagnostic sensitivity in amyotrophic lateral sclerosis: A systematic review using individual patient data. Clinical Neurophysiology, 2016, 127, 2684-2691. | 1.5 | 74 |
| 93 | Assessment of Eating Behavior Disturbance and Associated Neural Networks in Frontotemporal Dementia. JAMA Neurology, 2016, 73, 282. | 9.0 | 74 |
| 94 | Chemotherapy-Induced Peripheral Neuropathy in Long-term Survivors of Childhood Cancer. JAMA Neurology, 2018, 75, 980. | 9.0 | 73 |
| 95 | Eating behavior in frontotemporal dementia. Neurology, 2015, 85, 1310-1317. | 1.1 | 72 |
| 96 | Physiological changes in neurodegeneration â€" mechanistic insights and clinical utility. Nature Reviews Neurology, 2018, 14, 259-271. | 10.1 | 72 |
| 97 | Defining the mechanisms that underlie cortical hyperexcitability in amyotrophic lateral sclerosis. Experimental Neurology, 2009, 220, 177-182. | 4.1 | 71 |
| 98 | Conduction block in carpal tunnel syndrome. Brain, 1999, 122, 933-941. | 7.6 | 69 |
| 99 | Early, progressive, and sustained dysfunction of sensory axons underlies paclitaxelâ€induced neuropathy. Muscle and Nerve, 2011, 43, 367-374. | 2.2 | 69 |
| 100 | Diagnostic Utility of Gold Coast Criteria in <scp>Amyotrophic Lateral Sclerosis</scp>. Annals of Neurology, 2021, 89, 979-986. | 5.3 | 68 |
| 101 | The effects of alterations in conditioning stimulus intensity on short interval intracortical inhibition. Brain Research, 2009, 1273, 39-47. | 2.2 | 67 |
| 102 | Imbalance of cortical facilitatory and inhibitory circuits underlies hyperexcitability in ALS. Neurology, 2018, 91, e1669-e1676. | 1.1 | 67 |
| 103 | Temperature dependence of excitability indices of human cutaneous afferents. , 1999, 22, 51-60. | | 66 |
| 104 | Sleep disorders and respiratory function in amyotrophic lateral sclerosis. Sleep Medicine Reviews, 2016, 26, 33-42. | 8.5 | 65 |
| 105 | Modulatory Effects on Axonal Function After Intravenous Immunoglobulin Therapy in Chronic Inflammatory Demyelinating Polyneuropathy. Archives of Neurology, 2011, 68, 862. | 4.5 | 63 |
| 106 | Guillain-Barre syndrome in Asia. Journal of Neurology, Neurosurgery and Psychiatry, 2014, 85, 907-913. | 1.9 | 63 |
| 107 | Safety and tolerability of Triumeq in amyotrophic lateral sclerosis: the Lighthouse trial. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2019, 20, 595-604. | 1.7 | 63 |
| 108 | Measurement of axonal excitability: Consensus guidelines. Clinical Neurophysiology, 2020, 131, 308-323. | 1.5 | 63 |

| # | Article | IF | Citations |
|---|---|---|---|
| 109 | Safety and efficacy of ozanezumab in patients with amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Neurology, The, 2017, 16, 208-216. | 10.2 | 62 |
| 110 | The neural correlates and clinical characteristics of psychosis in the frontotemporal dementia continuum and the C9orf72 expansion. NeuroImage: Clinical, 2017, 13, 439-445. | 2.7 | 60 |
| 111 | Optimal clinical assessment strategies for chemotherapy-induced peripheral neuropathy (CIPN): a systematic review and Delphi survey. Supportive Care in Cancer, 2017, 25, 3485-3493. | 2.2 | 59 |
| 112 | Riluzole exerts transient modulating effects on cortical and axonal hyperexcitability in ALS. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2016, 17, 580-588. | 1.7 | 58 |
| 113 | Mutation in the Na+ channel subunit SCN1B produces paradoxical changes in peripheral nerve excitability. Brain, 2005, 128, 1841-1846. | 7.6 | 54 |
| 114 | Fatigue and activity dependent changes in axonal excitability in amyotrophic lateral sclerosis. Journal of Neurology, Neurosurgery and Psychiatry, 2007, 78, 1202-1208. | 1.9 | 54 |
| 115 | A novel tool to detect behavioural symptoms in ALS. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2014, 15, 298-304. | 1.7 | 53 |
| 116 | Randomized, Controlled Trial of the Effect of Dietary Potassium Restriction on Nerve Function in CKD. Clinical Journal of the American Society of Nephrology: CJASN, 2017, 12, 1569-1577. | 4.5 | 53 |
| 117 | Isolated bulbar phenotype of amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders, 2011, 12, 283-289. | 2.1 | 52 |
| 118 | What are the roles of carers in decision-making for amyotrophic lateral sclerosis multidisciplinary care?. Patient Preference and Adherence, 2013, 7, 171. | 1.8 | 52 |
| 119 | Utility of threshold tracking transcranial magnetic stimulation in ALS. Clinical Neurophysiology Practice, 2018, 3, 164-172. | 1.4 | 51 |
| 120 | Neurophysiological and clinical outcomes in chemotherapy-induced neuropathy in cancer. Clinical Neurophysiology, 2017, 128, 1166-1175. | 1.5 | 50 |
| 121 | Study of motor asymmetry in ALS indicates an effect of limb dominance on onset and spread of weakness, and an important role for upper motor neurons. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2014, 15, 481-487. | 1.7 | 48 |
| 122 | Systemic metabolism in frontotemporal dementia. Neurology, 2014, 83, 1812-1818. | 1.1 | 48 |
| 123 | Motor neuron disease-frontotemporal dementia: a clinical continuum. Expert Review of Neurotherapeutics, 2015, 15, 509-522. | 2.8 | 48 |
| 124 | Multifocal motor neuropathy: controversies and priorities. Journal of Neurology, Neurosurgery and Psychiatry, 2020, 91, 140-148. | 1.9 | 48 |
| 125 | The impact of cognitive and behavioral impairment in amyotrophic lateral sclerosis. Expert Review of Neurotherapeutics, 2020, 20, 281-293. | 2.8 | 48 |
| 126 | Evidence for polygenic and oligogenic basis of Australian sporadic amyotrophic lateral sclerosis. Journal of Medical Genetics, 2021, 58, 87-95. | 3.2 | 48 |

| # | Article | IF | Citations |
|---|---|---|---|
| 127 | Neurophysiological index as a biomarker for ALS progression: Validity of mixed effects models. Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders, 2011, 12, 33-38. | 2.1 | 47 |
| 128 | FOSMN syndrome. Neurology, 2012, 79, 73-79. | 1.1 | 47 |
| 129 | Dissociated lower limb muscle involvement in amyotrophic lateral sclerosis. Journal of Neurology, 2015, 262, 1424-1432. | 3.6 | 47 |
| 130 | Lipid Metabolism and Survival Across the Frontotemporal Dementia-Amyotrophic Lateral Sclerosis Spectrum: Relationships to Eating Behavior and Cognition. Journal of Alzheimer's Disease, 2017, 61, 773-783. | 2.6 | 47 |
| 131 | Split-hand plus sign in ALS: Differential involvement of the flexor pollicis longus and intrinsic hand muscles. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2013, 14, 315-318. | 1.7 | 46 |
| 132 | Evidence for a causal relationship between hyperkalaemia and axonal dysfunction in end-stage kidney disease. Clinical Neurophysiology, 2014, 125, 179-185. | 1.5 | 46 |
| 133 | Diagnostic criteria in amyotrophic lateral sclerosis. Neurology, 2016, 87, 684-690. | 1.1 | 46 |
| 134 | Measuring network disruption in neurodegenerative diseases: New approaches using signal analysis. Journal of Neurology, Neurosurgery and Psychiatry, 2019, 90, 1011-1020. | 1.9 | 45 |
| 135 | Cortical hyperexcitability evolves with disease progression in ALS. Annals of Clinical and Translational Neurology, 2020, 7, 733-741. | 3.7 | 45 |
| 136 | ALS pathophysiology: Insights from the split-hand phenomenon. Clinical Neurophysiology, 2014, 125, 186-193. | 1.5 | 44 |
| 137 | Emotion processing deficits distinguish pure amyotrophic lateral sclerosis from frontotemporal dementia. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2014, 15, 39-46. | 1.7 | 44 |
| 138 | Nerve excitability properties in lower-limb motor axons: Evidence for a length-dependent gradient. Muscle and Nerve, 2004, 29, 645-655. | 2.2 | 43 |
| 139 | Energy expenditure in frontotemporal dementia: a behavioural and imaging study. Brain, 2017, 140, 171-183. | 7.6 | 43 |
| 140 | Axonal Excitability in Amyotrophic Lateral Sclerosis. Neurotherapeutics, 2017, 14, 78-90. | 4.4 | 43 |
| 141 | Association of Leucine-Rich Glioma Inactivated Protein 1, Contactin-Associated Protein 2, and Contactin 2 Antibodies With Clinical Features and Patient-Reported Pain in Acquired Neuromyotonia. JAMA Neurology, 2018, 75, 1519. | 9.0 | 43 |
| 142 | Progressive axonal dysfunction and clinical impairment in amyotrophic lateral sclerosis. Clinical Neurophysiology, 2012, 123, 2460-2467. | 1.5 | 42 |
| 143 | Quantitative ultrasound of denervated hand muscles. Muscle and Nerve, 2015, 52, 221-230. | 2.2 | 42 |
| 144 | A Phase 2, Double-Blind, Randomized, Dose-Ranging Trial Of Reldesemtiv In Patients With ALS. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2021, 22, 287-299. | 1.7 | 42 |

| # | Article | IF | Citations |
|---|---|---|---|
| 145 | Purple pigments: The pathophysiology of acute porphyric neuropathy. Clinical Neurophysiology, 2011, 122, 2336-2344. | 1.5 | 40 |
| 146 | Advance care planning in motor neuron disease: A qualitative study of caregiver perspectives. Palliative Medicine, 2016, 30, 471-478. | 3.1 | 40 |
| 147 | Eating peptides: biomarkers of neurodegeneration in amyotrophic lateral sclerosis and frontotemporal dementia. Annals of Clinical and Translational Neurology, 2019, 6, 486-495. | 3.7 | 40 |
| 148 | Regional thalamic MRI as a marker of widespread cortical pathology and progressive frontotemporal involvement in amyotrophic lateral sclerosis. Journal of Neurology, Neurosurgery and Psychiatry, 2018, 89, 1250-1258. | 1.9 | 39 |
| 149 | ALS is a multistep process in South Korean, Japanese, and Australian patients. Neurology, 2020, 94, e1657-e1663. | 1.1 | 39 |
| 150 | Neuropathy, axonal Na+/K+ pump function and activity-dependent excitability changes in end-stage kidney disease. Clinical Neurophysiology, 2006, 117, 992-999. | 1.5 | 38 |
| 151 | The Pathophysiology of Oxaliplatin-Induced Neurotoxicity. Current Medicinal Chemistry, 2006, 13, 2901-2907. | 2.4 | 38 |
| 152 | Semantic deficits in amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2015, 16, 46-53. | 1.7 | 38 |
| 153 | Genome-wide study of DNA methylation shows alterations in metabolic, inflammatory, and cholesterol pathways in ALS. Science Translational Medicine, 2022, 14, eabj0264. | 12.4 | 38 |
| 154 | Neurofascinâ€155 IGG4 Neuropathy: Pathophysiological Insights, Spectrum of Clinical Severity and Response To treatment. Muscle and Nerve, 2018, 57, 848-851. | 2.2 | 37 |
| 155 | Adaptation of motor function after spinal cord injury: novel insights into spinal shock. Brain, 2011, 134, 495-505. | 7.6 | 36 |
| 156 | Dysfunction of axonal membrane conductances in adolescents and young adults with spinal muscular atrophy. Brain, 2011, 134, 3185-3197. | 7.6 | 35 |
| 157 | Early identification of 'acute-onset' chronic inflammatory demyelinating polyneuropathy. Brain, 2014, 137, 2155-2163. | 7.6 | 35 |
| 158 | Axonal Ion Channel Dysfunction inC9orf72Familial Amyotrophic Lateral Sclerosis. JAMA Neurology, 2015, 72, 49. | 9.0 | 35 |
| 159 | Primary lateral sclerosis and the amyotrophic lateral sclerosisâ€“frontotemporal dementia spectrum. Journal of Neurology, 2018, 265, 1819-1828. | 3.6 | 35 |
| 160 | Novel approaches to diagnosis and management of hereditary transthyretin amyloidosis. Journal of Neurology, Neurosurgery and Psychiatry, 2022, 93, 668-678. | 1.9 | 35 |
| 161 | Utility of transcranial magnetic stimulation in delineating amyotrophic lateral sclerosis pathophysiology. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2013, 116, 561-575. | 1.8 | 34 |
| 162 | The evolution of motor cortical dysfunction in amyotrophic lateral sclerosis. Clinical Neurophysiology, 2017, 128, 1075-1082. | 1.5 | 34 |

| # | Article | IF | Citations |
|---|---|---|---|
| 163 | Inter-session reliability of short-interval intracortical inhibition measured by threshold tracking TMS. Neuroscience Letters, 2018, 674, 18-23. | 2.1 | 34 |
| 164 | Threshold tracking transcranial magnetic stimulation: Effects of age and gender on motor cortical function. Clinical Neurophysiology, 2016, 127, 2355-2361. | 1.5 | 33 |
| 165 | Study protocol of RESCUE-ALS: A Phase 2, randomised, double-blind, placebo-controlled study in early symptomatic amyotrophic lateral sclerosis patients to assess bioenergetic catalysis with CNM-Au8 as a mechanism to slow disease progression. BMJ Open, 2021, 11, e041479. | 1.9 | 33 |
| 166 | Changes in excitability and impulse transmission following prolonged repetitive activity in normal subjects and patients with a focal nerve lesion. Brain, 1996, 119, 2029-2037. | 7.6 | 32 |
| 167 | Patterns of clinical and electrodiagnostic abnormalities in early amyotrophic lateral sclerosis. Muscle and Nerve, 2014, 50, 894-899. | 2.2 | 32 |
| 168 | Potential structural and functional biomarkers of upper motor neuron dysfunction in ALS. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2016, 17, 85-92. | 1.7 | 32 |
| 169 | Health, wellbeing and lived experiences of adults with SMA: a scoping systematic review. Orphanet Journal of Rare Diseases, 2020, 15, 70. | 2.7 | 32 |
| 170 | Riluzole therapy for motor neurone disease: An early Australian experience (1996â€“2002). Journal of Clinical Neuroscience, 2006, 13, 78-83. | 1.5 | 31 |
| 171 | Development of a model to guide decision making in amyotrophic lateral sclerosis multidisciplinary care. Health Expectations, 2015, 18, 1769-1782. | 2.6 | 31 |
| 172 | Physiological Processes Underlying Short Interval Intracortical Facilitation in the Human Motor Cortex. Frontiers in Neuroscience, 2018, 12, 240. | 2.8 | 31 |
| 173 | Loss of the metabolism and sleep regulating neuronal populations expressing orexin and oxytocin in the hypothalamus in amyotrophic lateral sclerosis. Neuropathology and Applied Neurobiology, 2021, 47, 979-989. | 3.2 | 31 |
| 174 | Dissecting the Mechanisms Underlying Short-Interval Intracortical Inhibition Using Exercise. Cerebral Cortex, 2011, 21, 1639-1644. | 2.9 | 30 |
| 175 | Fasciculation anxiety syndrome in clinicians. Journal of Neurology, 2013, 260, 1743-1747. | 3.6 | 30 |
| 176 | Effects of Axonal Ion Channel Dysfunction on Quality of Life in Type 2 Diabetes. Diabetes Care, 2013, 36, 1272-1277. | 8.6 | 30 |
| 177 | Detection of fasciculations in amyotrophic lateral sclerosis: The optimal ultrasound scan time. Muscle and Nerve, 2017, 56, 1068-1071. | 2.2 | 30 |
| 178 | Amyotrophic lateral sclerosis: Origins traced to impaired balance between neural excitation and inhibition in the neonatal period. Muscle and Nerve, 2019, 60, 232-235. | 2.2 | 30 |
| 179 | Phenotypic variability in ALS-FTD and effect on survival. Neurology, 2020, 94, e2005-e2013. | 1.1 | 30 |
| 180 | Paraesthesiae Induced by Prolonged high Frequency Stimulation of Human Cutaneous Afferents. Journal of Physiology, 1997, 501, 461-471. | 2.9 | 29 |

| # | Article | IF | Citations |
|---|---|---|---|
| 181 | Corticomotoneuronal function and hyperexcitability in acquired neuromyotonia. Brain, 2010, 133, 2727-2733. | 7.6 | 29 |
| 182 | Axonal dysfunction prior to neuropathy onset in type 1 diabetes. Diabetes/Metabolism Research and Reviews, 2013, 29, 53-59. | 4.0 | 29 |
| 183 | Cerebellar neuronal loss in amyotrophic lateral sclerosis cases with <scp>ATXN</scp>2 intermediate repeat expansions. Annals of Neurology, 2016, 79, 295-305. | 5.3 | 29 |
| 184 | Interrogating cortical function with transcranial magnetic stimulation: insights from neurodegenerative disease and stroke. Journal of Neurology, Neurosurgery and Psychiatry, 2019, 90, 47-57. | 1.9 | 29 |
| 185 | The underacknowledged PPA-ALS. Neurology, 2019, 92, e1354-e1366. | 1.1 | 29 |
| 186 | Consensus for experimental design in electromyography (CEDE) project: Terminology matrix. Journal of Electromyography and Kinesiology, 2021, 59, 102565. | 1.7 | 29 |
| 187 | Characterizing Sexual Behavior inÂFrontotemporal Dementia. Journal of Alzheimer's Disease, 2015, 46, 677-686. | 2.6 | 28 |
| 188 | Motor neurone disease: progress and challenges. Medical Journal of Australia, 2017, 206, 357-362. | 1.7 | 28 |
| 189 | Characteristics and risk factors of bortezomib induced peripheral neuropathy: A systematic review of phase III trials. Hematological Oncology, 2020, 38, 229-243. | 1.7 | 28 |
| 190 | Pathophysiologic insights into motor axonal function in Kennedy disease. Neurology, 2007, 69, 1828-1835. | 1.1 | 27 |
| 191 | Threshold behaviour of human axons explored using subthreshold perturbations to membrane potential. Journal of Physiology, 2009, 587, 491-504. | 2.9 | 27 |
| 192 | A visual MRI atrophy rating scale for the amyotrophic lateral sclerosis-frontotemporal dementia continuum. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2014, 15, 226-234. | 1.7 | 27 |
| 193 | Distinct TDP-43 inclusion morphologies in frontotemporal lobar degeneration with and without amyotrophic lateral sclerosis. Acta Neuropathologica Communications, 2017, 5, 76. | 5.2 | 27 |
| 194 | Comparison of crossâ€sectional areas and distalâ€proximal nerve ratios in amyotrophic lateral sclerosis. Muscle and Nerve, 2018, 58, 777-783. | 2.2 | 27 |
| 195 | Ischaemia induces paradoxical changes in axonal excitability in end-stage kidney disease. Brain, 2006, 129, 1585-1592. | 7.6 | 26 |
| 196 | Ischaemic sensitivity of axons in carpal tunnel syndrome. Journal of the Peripheral Nervous System, 2009, 14, 190-200. | 3.1 | 26 |
| 197 | Apraxia and Motor Dysfunction in Corticobasal Syndrome. PLoS ONE, 2014, 9, e92944. | 2.5 | 26 |
| 198 | A longer diagnostic interval is a risk for depression in amyotrophic lateral sclerosis. Palliative and Supportive Care, 2015, 13, 1019-1024. | 1.0 | 26 |

| # | Article | IF | Citations |
|---|---|---|---|
| 199 | The Evolution of Caregiver Burden inÂFrontotemporal Dementia with and without Amyotrophic Lateral Sclerosis. Journal of Alzheimer's Disease, 2015, 49, 875-885. | 2.6 | 26 |
| 200 | Segmental motoneuronal dysfunction is a feature of amyotrophic lateral sclerosis. Clinical Neurophysiology, 2015, 126, 828-836. | 1.5 | 26 |
| 201 | Cerebellar tract alterations in PLS and ALS. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2019, 20, 281-284. | 1.7 | 26 |
| 202 | Altered serum protein levels in frontotemporal dementia and amyotrophic lateral sclerosis indicate calcium and immunity dysregulation. Scientific Reports, 2020, 10, 13741. | 3.3 | 26 |
| 203 | Occasional essay: Upper motor neuron syndrome in amyotrophic lateral sclerosis. Journal of Neurology, Neurosurgery and Psychiatry, 2020, 91, 227-234. | 1.9 | 26 |
| 204 | Plasticity of lower limb motor axons after cervical cord injury. Clinical Neurophysiology, 2009, 120, 204-209. | 1.5 | 25 |
| 205 | Flecainide in Amyotrophic Lateral Sclerosis as a Neuroprotective Strategy (FANS): A Randomized Placebo-Controlled Trial. EBioMedicine, 2015, 2, 1916-1922. | 6.1 | 25 |
| 206 | Motor unit remodelling in multifocal motor neuropathy: The importance of axonal loss. Clinical Neurophysiology, 2017, 128, 2022-2028. | 1.5 | 25 |
| 207 | Correlation between markers of peripheral nerve function and structure in type 1 diabetes. Diabetes/Metabolism Research and Reviews, 2018, 34, e3028. | 4.0 | 25 |
| 208 | Nerve biopsy: Current indications and decision tools. Muscle and Nerve, 2021, 64, 125-139. | 2.2 | 25 |
| 209 | Evolution of peripheral nerve function in humans: novel insights from motor nerve excitability. Journal of Physiology, 2013, 591, 273-286. | 2.9 | 24 |
| 210 | Syntactic comprehension deficits across the FTD-ALS continuum. Neurobiology of Aging, 2016, 41, 11-18. | 3.1 | 24 |
| 211 | Utility of maximum perfusion intensity as an ultrasonographic marker of intraneural blood flow. Muscle and Nerve, 2017, 55, 77-83. | 2.2 | 24 |
| 212 | Structural and functional papez circuit integrity in amyotrophic lateral sclerosis. Brain Imaging and Behavior, 2018, 12, 1622-1630. | 2.1 | 24 |
| 213 | Cortical hyperexcitability: Diagnostic and pathogenic biomarker of ALS. Neuroscience Letters, 2021, 759, 136039. | 2.1 | 24 |
| 214 | Changes in human sensory axonal excitability induced by focal nerve compression. Journal of Physiology, 2010, 588, 1737-1745. | 2.9 | 23 |
| 215 | Maladaptation of cortical circuits underlies fatigue and weakness in ALS. Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders, 2011, 12, 414-420. | 2.1 | 23 |
| 216 | Paclitaxel-induced neuropathy: potential association of MAPT and GSK3B genotypes. BMC Cancer, 2014, 14, 993. | 2.6 | 23 |

| # | Article | IF | Citations |
|---|---|---|---|
| 217 | Terra incognitaâ€"cerebellar contributions to neuropsychiatric and cognitive dysfunction in behavioral variant frontotemporal dementia. Frontiers in Aging Neuroscience, 2015, 7, 121. | 3.4 | 23 |
| 218 | Short-term peripheral nerve stimulation ameliorates axonal dysfunction after spinal cord injury. Journal of Neurophysiology, 2015, 113, 3209-3218. | 1.8 | 23 |
| 219 | Cortical contributions to the flail leg syndrome: Pathophysiological insights. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2016, 17, 389-396. | 1.7 | 23 |
| 220 | Cognitive and Behavioral Symptoms in ALSFTD. Journal of Geriatric Psychiatry and Neurology, 2016, 29, 3-10. | 2.3 | 23 |
| 221 | Mouse models of frontotemporal dementia: A comparison of phenotypes with clinical symptomatology. Neuroscience and Biobehavioral Reviews, 2017, 74, 126-138. | 6.1 | 23 |
| 222 | Peripheral nerve diffusion tensor imaging as a measure of disease progression in ALS. Journal of Neurology, 2017, 264, 882-890. | 3.6 | 23 |
| 223 | Physiological processes influencing motor-evoked potential duration with voluntary contraction. Journal of Neurophysiology, 2017, 117, 1156-1162. | 1.8 | 23 |
| 224 | In vivo evidence for reduced ion channel expression in motor axons of patients with amyotrophic lateral sclerosis. Journal of Physiology, 2018, 596, 5379-5396. | 2.9 | 23 |
| 225 | Functional Biomarkers for Amyotrophic Lateral Sclerosis. Frontiers in Neurology, 2018, 9, 1141. | 2.4 | 23 |
| 226 | Cortical excitability differences in hand muscles follow a splitâ€hand pattern in healthy controls. Muscle and Nerve, 2014, 49, 836-844. | 2.2 | 22 |
| 227 | Axonal damage in central and peripheral nervous system inflammatory demyelinating diseases. Current Opinion in Neurology, 2016, 29, 213-221. | 3.6 | 22 |
| 228 | Motor cortical dysfunction develops in spinocerebellar ataxia type 3. Clinical Neurophysiology, 2016, 127, 3418-3424. | 1.5 | 22 |
| 229 | Novel therapies in development that inhibit motor neuron hyperexcitability in amyotrophic lateral sclerosis. Expert Review of Neurotherapeutics, 2016, 16, 1147-1154. | 2.8 | 22 |
| 230 | Pathophysiology of motor dysfunction in a childhood motor neuron disease caused by mutations in the riboflavin transporter. Clinical Neurophysiology, 2016, 127, 911-918. | 1.5 | 22 |
| 231 | Amyotrophic lateral sclerosis as a multi-step process: an Australia population study. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2019, 20, 532-537. | 1.7 | 22 |
| 232 | Quantification of Small Fiber Neuropathy in Chemotherapy-Treated Patients. Journal of Pain, 2020, 21, 44-58. | 1.4 | 22 |
| 233 | Early focality and spread of cortical dysfunction in amyotrophic lateral sclerosis: A regional study across the motor cortices. Clinical Neurophysiology, 2020, 131, 958-966. | 1.5 | 22 |
| 234 | Consensus for experimental design in electromyography (CEDE) project: High-density surface electromyography matrix. Journal of Electromyography and Kinesiology, 2022, 64, 102656. | 1.7 | 22 |

| # | Article | IF | Citations |
|---|---|---|---|
| 235 | Hyperexcitability, persistent Na+ conductances and neurodegeneration in amyotrophic lateral sclerosis. Experimental Neurology, 2009, 218, 1-4. | 4.1 | 21 |
| 236 | Hyperexcitability and amyotrophic lateral sclerosis. Neurology, 2012, 78, 1544-1545. | 1.1 | 21 |
| 237 | Botulinum toxin modulates cortical maladaptation in postâ€stroke spasticity. Muscle and Nerve, 2013, 48, 93-99. | 2.2 | 21 |
| 238 | Chemotherapy and peripheral neuropathy. Neurological Sciences, 2021, 42, 4109-4121. | 1.9 | 21 |
| 239 | The importance of offering early genetic testing in everyone with amyotrophic lateral sclerosis. Brain, 2022, 145, 1207-1210. | 7.6 | 21 |
| 240 | What is impact?: Figure 1. Journal of Neurology, Neurosurgery and Psychiatry, 2012, 83, 1-2. | 1.9 | 20 |
| 241 | Progress towards therapy in motor neuron disease. Nature Reviews Neurology, 2018, 14, 65-66. | 10.1 | 20 |
| 242 | The burden of apathy for caregivers of patients with amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2018, 19, 599-605. | 1.7 | 20 |
| 243 | Fasciculation intensity and disease progression in amyotrophic lateral sclerosis. Clinical Neurophysiology, 2018, 129, 2149-2154. | 1.5 | 20 |
| 244 | Paradox of amyotrophic lateral sclerosis and energy metabolism. Journal of Neurology, Neurosurgery and Psychiatry, 2018, 89, 1013-1014. | 1.9 | 20 |
| 245 | TDP-43 levels in the brain tissue of ALS cases with and without C9ORF72 or ATXN2 gene expansions. Neurology, 2019, 93, e1748-e1755. | 1.1 | 20 |
| 246 | Identity by descent analysis identifies founder events and links SOD1 familial and sporadic ALS cases. Npj Genomic Medicine, 2020, 5, 32. | 3.8 | 20 |
| 247 | Metabolic and lifestyle risk factors for chemotherapy-induced peripheral neuropathy in taxane and platinum-treated patients: a systematic review. Journal of Cancer Survivorship, 2023, 17, 222-236. | 2.9 | 20 |
| 248 | Regional motor cortex dysfunction in amyotrophic lateral sclerosis. Annals of Clinical and Translational Neurology, 2019, 6, 1373-1382. | 3.7 | 19 |
| 249 | Conduction block in immuneâ€mediated neuropathy: paranodopathy versus axonopathy. European Journal of Neurology, 2019, 26, 1121-1129. | 3.3 | 19 |
| 250 | Taxane-induced peripheral neuropathy: differences in patient report and objective assessment. Supportive Care in Cancer, 2020, 28, 4459-4466. | 2.2 | 19 |
| 251 | Utilizing natural activity to dissect the pathophysiology of acute oxaliplatin-induced neuropathy. Experimental Neurology, 2011, 227, 120-127. | 4.1 | 18 |
| 252 | In vivo loss of slow potassium channel activity in individuals with benign familial neonatal epilepsy in remission. Brain, 2012, 135, 3144-3152. | 7.6 | 18 |

| # | Article | IF | Citations |
|---|---|---|---|
| 253 | Physiology and pathophysiology of myelinated nerve fibers. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2013, 115, 43-53. | 1.8 | 18 |
| 254 | Effects of Hemodiafiltration and High Flux Hemodialysis on Nerve Excitability in End-Stage Kidney Disease. PLoS ONE, 2013, 8, e59055. | 2.5 | 18 |
| 255 | Safety and efficacy of dimethyl fumarate in ALS: randomised controlled study. Annals of Clinical and Translational Neurology, 2021, 8, 1991-1999. | 3.7 | 18 |
| 256 | Ischemic resistance of cutaneous afferents and motor axons in patients with amyotrophic lateral sclerosis. , 1998, 21, 1692-1700. | | 17 |
| 257 | Nerve Excitability Measures: Biophysical Basis and Use in the Investigation of Peripheral Nerve Disease. , 2005, , 113-129. | | 17 |
| 258 | Nerve compression, membrane excitability, and symptoms of carpal tunnel syndrome. Muscle and Nerve, 2011, 44, 402-409. | 2.2 | 17 |
| 259 | In vivo evidence of reduced nodal and paranodal conductances in type 1 diabetes. Clinical Neurophysiology, 2016, 127, 1700-1706. | 1.5 | 17 |
| 260 | The Effect of Diabetes on Cortical Function in Stroke: Implications for Poststroke Plasticity. Diabetes, 2017, 66, 1661-1670. | 0.6 | 17 |
| 261 | Amyotrophic lateral sclerosis diagnostic index. Neurology, 2019, 92, e536-e547. | 1.1 | 17 |
| 262 | The effect of coil type and limb dominance in the assessment of lower-limb motor cortex excitability using TMS. Neuroscience Letters, 2019, 699, 84-90. | 2.1 | 17 |
| 263 | Behavioural changes predict poorer survival in amyotrophic lateral sclerosis. Brain and Cognition, 2021, 150, 105710. | 1.8 | 17 |
| 264 | Biomarker discovery and development for frontotemporal dementia and amyotrophic lateral sclerosis. Brain, 2022, 145, 1598-1609. | 7.6 | 17 |
| 265 | Precise correlation between structural and electrophysiological disturbances in MADSAM neuropathy. Neuromuscular Disorders, 2015, 25, 904-907. | 0.6 | 16 |
| 266 | Immune dysregulation in patients with carpal tunnel syndrome. Scientific Reports, 2017, 7, 8218. | 3.3 | 16 |
| 267 | Aerobic exercise training may improve nerve function in type 2 diabetes and preâ€diabetes: A systematic review. Diabetes/Metabolism Research and Reviews, 2019, 35, e3099. | 4.0 | 16 |
| 268 | The impact of obesity on neuropathy outcomes for paclitaxel- and oxaliplatin-treated cancer survivors. Journal of Cancer Survivorship, 2022, 16, 223-232. | 2.9 | 16 |
| 269 | Gold Coast diagnostic criteria: Implications for <scp>ALS</scp> diagnosis and clinical trial enrollment. Muscle and Nerve, 2021, 64, 532-537. | 2.2 | 16 |
| 270 | Tackling clinical heterogeneity across the amyotrophic lateral sclerosisâ€“frontotemporal dementia spectrum using a transdiagnostic approach. Brain Communications, 2021, 3, fcab257. | 3.3 | 16 |

| # | Article | IF | Citations |
|---|---|---|---|
| 271 | Haemodialysis alters peripheral nerve morphology in end-stage kidney disease. Clinical Neurophysiology, 2017, 128, 281-286. | 1.5 | 15 |
| 272 | Ectopic impulse generation in peripheral nerve hyperexcitability syndromes and amyotrophic lateral sclerosis. Clinical Neurophysiology, 2018, 129, 974-980. | 1.5 | 15 |
| 273 | Anti-MAG neuropathy: Role of IgM antibodies, the paranodal junction and juxtaparanodal potassium channels. Clinical Neurophysiology, 2018, 129, 2162-2169. | 1.5 | 15 |
| 274 | Potassium control in chronic kidney disease: implications for neuromuscular function. Internal Medicine Journal, 2019, 49, 817-825. | 0.8 | 15 |
| 275 | Axonal dysfunction, dysmyelination, and conduction failure in hereditary neuropathy with liability to pressure palsies. Muscle and Nerve, 2014, 49, 858-865. | 2.2 | 14 |
| 276 | Axonal dysfunction with voltage gated potassium channel complex antibodies. Experimental Neurology, 2014, 261, 337-342. | 4.1 | 14 |
| 277 | Continuous subcutaneous insulin infusion preserves axonal function in type 1 diabetes mellitus. Diabetes/Metabolism Research and Reviews, 2015, 31, 175-182. | 4.0 | 14 |
| 278 | The utility of the Total Neuropathy Score as an instrument to assess neuropathy severity in chronic kidney disease: A validation study. Clinical Neurophysiology, 2018, 129, 889-894. | 1.5 | 14 |
| 279 | Neural correlates of changes in sexual function in frontotemporal dementia: implications for reward and physiological functioning. Journal of Neurology, 2018, 265, 2562-2572. | 3.6 | 14 |
| 280 | Cortical excitability varies across different muscles. Journal of Neurophysiology, 2018, 120, 1397-1403. | 1.8 | 14 |
| 281 | Clinical and neuroimaging investigations of language disturbance in frontotemporal dementiaâ€“motor neuron disease patients. Journal of Neurology, 2019, 266, 921-933. | 3.6 | 14 |
| 282 | Electrophysiological and phenotypic profiles of taxane-induced neuropathy. Clinical Neurophysiology, 2020, 131, 1979-1985. | 1.5 | 14 |
| 283 | Pathological manifestation of human endogenous retrovirus K in frontotemporal dementia. Communications Medicine, 2021, 1, . | 4.2 | 14 |
| 284 | Excitability differences in lower-limb motor axons during and after ischemia. Muscle and Nerve, 2005, 31, 205-213. | 2.2 | 13 |
| 285 | Chapter 17 Assessment of nerve excitability properties in peripheral nerve disease. Handbook of Clinical Neurophysiology, 2006, 7, 381-403. | 0.0 | 13 |
| 286 | Corticospinal tract dysfunction and development of amyotrophic lateral sclerosis following electrical injury. Muscle and Nerve, 2010, 42, 288-292. | 2.2 | 13 |
| 287 | Does dysfunction of the mirror neuron system contribute to symptoms in amyotrophic lateral sclerosis?. Clinical Neurophysiology, 2015, 126, 1288-1294. | 1.5 | 13 |
| 288 | Dynamic muscle ultrasound identifies upper motor neuron involvement in amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2017, 18, 404-410. | 1.7 | 13 |

| # | Article | IF | Citations |
|---|---|---|---|
| 289 | Tracking small sensory nerve action potentials in human axonal excitability studies. Journal of Neuroscience Methods, 2018, 298, 45-53. | 2.5 | 13 |
| 290 | Relative contributions of diabetes and chronic kidney disease to neuropathy development in diabetic nephropathy patients. Clinical Neurophysiology, 2019, 130, 2088-2095. | 1.5 | 13 |
| 291 | Vasculitic neuropathy: Comparison of clinical predictors with histopathological outcome. Muscle and Nerve, 2019, 59, 643-649. | 2.2 | 13 |
| 292 | Isaacs syndrome: the frontier of neurology, psychiatry, immunology and cancer. Journal of Neurology, Neurosurgery and Psychiatry, 2020, 91, 1243-1244. | 1.9 | 13 |
| 293 | Regional callosal integrity and bilaterality of limb weakness in amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2020, 21, 396-402. | 1.7 | 13 |
| 294 | Pathophysiology and Treatment of Non-motor Dysfunction in Amyotrophic Lateral Sclerosis. CNS Drugs, 2021, 35, 483-505. | 5.9 | 13 |
| 295 | Effects of mexiletine on hyperexcitability in sporadic amyotrophic lateral sclerosis: Preliminary findings from a small phase II randomized controlled trial. Muscle and Nerve, 2021, 63, 371-383. | 2.2 | 13 |
| 296 | Predicting a Positive Response to Intravenous Immunoglobulin in Isolated Lower Motor Neuron Syndromes. PLoS ONE, 2011, 6, e27041. | 2.5 | 13 |
| 297 | Appearance, phenomenology and diagnostic utility of the split hand in amyotrophic lateral sclerosis. Neurodegenerative Disease Management, 2011, 1, 457-462. | 2.2 | 12 |
| 298 | Implications of structural and functional brain changes in amyotrophic lateral sclerosis. Expert Review of Neurotherapeutics, 2018, 18, 407-419. | 2.8 | 12 |
| 299 | Respiratory function and cognitive profile in amyotrophic lateral sclerosis. European Journal of Neurology, 2020, 27, 685-691. | 3.3 | 12 |
| 300 | Spinal muscular atrophy â€" the dawning of a new era. Nature Reviews Neurology, 2020, 16, 593-594. | 10.1 | 12 |
| 301 | Interrogating interneurone function using threshold tracking of the H reflex in healthy subjects and patients with motor neurone disease. Clinical Neurophysiology, 2020, 131, 1986-1996. | 1.5 | 12 |
| 302 | Neu-horizons: neuroprotection and therapeutic use of riluzole for the prevention of oxaliplatin-induced neuropathyâ€"a randomised controlled trial. Supportive Care in Cancer, 2021, 29, 1103-1110. | 2.2 | 12 |
| 303 | Pathophysiological associations of transcallosal dysfunction in ALS. European Journal of Neurology, 2021, 28, 1172-1180. | 3.3 | 12 |
| 304 | Motor cortical excitability predicts cognitive phenotypes in amyotrophic lateral sclerosis. Scientific Reports, 2021, 11, 2172. | 3.3 | 12 |
| 305 | Weekly Paclitaxel-Induced Neurotoxicity in Breast Cancer: Outcomes and Dose Response. Oncologist, 2021, 26, 366-374. | 3.7 | 12 |
| 306 | Apathy is associated with parietal cortical-subcortical dysfunction in ALS. Cortex, 2021, 145, 341-349. | 2.4 | 12 |

| # | Article | IF | Citations |
|---|---|---|---|
| 307 | Association of Cortical Hyperexcitability and Cognitive Impairment in Patients With Amyotrophic Lateral Sclerosis. Neurology, 2021, 96, e2090-e2097. | 1.1 | 12 |
| 308 | Functional characterisation of the amyotrophic lateral sclerosis risk locus GPX3/TNIP1. Genome Medicine, 2022, 14, 7. | 8.2 | 12 |
| 309 | Riluzole: a glimmer of hope in the treatment of motor neurone disease. Medical Journal of Australia, 2005, 182, 319-320. | 1.7 | 11 |
| 310 | Treatment approaches in motor neurone disease. Current Opinion in Neurology, 2016, 29, 581-591. | 3.6 | 11 |
| 311 | Diaphragm ultrasound in amyotrophic lateral sclerosis and other neuromuscular disorders. Clinical Neurophysiology, 2016, 127, 28-30. | 1.5 | 11 |
| 312 | Human cerebral evolution and the clinical syndrome of amyotrophic lateral sclerosis. Journal of Neurology, Neurosurgery and Psychiatry, 2019, 90, 570-575. | 1.9 | 11 |
| 313 | Interneuronal networks mediate cortical inhibition and facilitation. Clinical Neurophysiology, 2020, 131, 1000-1010. | 1.5 | 11 |
| 314 | Neural mechanisms of psychosis vulnerability and perceptual abnormalities in the ALSâ€FTD spectrum. Annals of Clinical and Translational Neurology, 2021, 8, 1576-1591. | 3.7 | 11 |
| 315 | Neurophysiological features of primary lateral sclerosis. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2020, 21, 11-17. | 1.7 | 11 |
| 316 | Apathy in amyotrophic lateral sclerosis: systematic review and meta-analysis of frequency, correlates, and outcomes. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2023, 24, 14-23. | 1.7 | 11 |
| 317 | Assessing chemotherapy-induced peripheral neuropathy with patient reported outcome measures: a systematic review of measurement properties and considerations for future use. Quality of Life Research, 2022, 31, 3091-3107. | 3.1 | 11 |
| 318 | TDP-43 in the hypoglossal nucleus identifies amyotrophic lateral sclerosis in behavioral variant frontotemporal dementia. Journal of the Neurological Sciences, 2016, 366, 197-201. | 0.6 | 10 |
| 319 | Effect of fampridine on axonal excitability in multiple sclerosis. Clinical Neurophysiology, 2016, 127, 2636-2642. | 1.5 | 10 |
| 320 | Laterality of motor cortical function measured by transcranial magnetic stimulation threshold tracking. Muscle and Nerve, 2017, 55, 424-427. | 2.2 | 10 |
| 321 | Fampridine treatment and walking distance in multiple sclerosis: A randomised controlled trial. Clinical Neurophysiology, 2017, 128, 93-99. | 1.5 | 10 |
| 322 | Motor neurone disease. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2018, 159, 345-357. | 1.8 | 10 |
| 323 | CNS cell typeâ€"specific gene profiling of P301S tau transgenic mice identifies genes dysregulated by progressive tau accumulation. Journal of Biological Chemistry, 2019, 294, 14149-14162. | 3.4 | 10 |
| 324 | Neural networks associated with body composition in frontotemporal dementia. Annals of Clinical and Translational Neurology, 2019, 6, 1707-1717. | 3.7 | 10 |

| # | Article | IF | Citations |
|---|---|---|---|
| 325 | Sonographic assessment of nerve blood flow in diabetic neuropathy. Diabetic Medicine, 2020, 37, 343-349. | 2.3 | 10 |
| 326 | Effect of Hemodiafiltration on the Progression of Neuropathy with Kidney Failure. Clinical Journal of the American Society of Nephrology: CJASN, 2021, 16, 1365-1375. | 4.5 | 10 |
| 327 | Monomelic amyotrophy: non progressive atrophy of the upper limb. Journal of Clinical Neuroscience, 1999, 6, 353-355. | 1.5 | 9 |
| 328 | The standard of care in amyotrophic lateral sclerosis: a centralised multidisciplinary clinic encounter sets a new benchmark for a uniquely challenging neurodegenerative disorder. Journal of Neurology, Neurosurgery and Psychiatry, 2015, 86, 481-482. | 1.9 | 9 |
| 329 | Palliative care in amyotrophic lateral sclerosis. Lancet Neurology, The, 2015, 14, 347-348. | 10.2 | 9 |
| 330 | Cortical function and corticomotoneuronal adaptation in monomelic amyotrophy. Clinical Neurophysiology, 2017, 128, 1488-1495. | 1.5 | 9 |
| 331 | Excitability of sensory axons in amyotrophic lateral sclerosis. Clinical Neurophysiology, 2018, 129, 1472-1478. | 1.5 | 9 |
| 332 | Effects of hemodialysis on intraneural blood flow in endâ€stage kidney disease. Muscle and Nerve, 2018, 57, 287-293. | 2.2 | 9 |
| 333 | A unified model of the excitability of mouse sensory and motor axons. Journal of the Peripheral Nervous System, 2018, 23, 159-173. | 3.1 | 9 |
| 334 | Predictors of survival in frontotemporal lobar degeneration syndromes. Journal of Neurology, Neurosurgery and Psychiatry, 2021, 92, 425-433. | 1.9 | 9 |
| 335 | Distal excitability properties of median motor axons. Muscle and Nerve, 2001, 24, 1695-1698. | 2.2 | 8 |
| 336 | Threshold electrotonus and the assessment of nerve excitability in amyotrophic lateral sclerosis. Handbook of Clinical Neurophysiology, 2004, 4, 359-366. | 0.0 | 8 |
| 337 | Amyotrophic lateral sclerosis and the neuroprotective potential of exercise. Journal of Physiology, 2009, 587, 3759-3760. | 2.9 | 8 |
| 338 | Nerve Excitability. , 2012, , 345-365. | | 8 |
| 339 | ALS and neuromuscular disease: in search of the Holy Grail. Lancet Neurology, The, 2014, 13, 13-14. | 10.2 | 8 |
| 340 | Cardiometabolic health and risk of amyotrophic lateral sclerosis. Muscle and Nerve, 2017, 56, 721-725. | 2.2 | 8 |
| 341 | Selective Spatiotemporal Vulnerability of Central Nervous System Neurons to Pathologic TAR DNA-Binding Protein 43 in Aged Transgenic Mice. American Journal of Pathology, 2018, 188, 1447-1456. | 3.8 | 8 |
| 342 | Inherited Neuropathies. Seminars in Neurology, 2019, 39, 620-639. | 1.4 | 8 |

| # | Article | IF | Citations |
|---|---|---|---|
| 343 | Genetic and immunopathological analysis of CHCHD10 in Australian amyotrophic lateral sclerosis and frontotemporal dementia and transgenic TDP-43 mice. Journal of Neurology, Neurosurgery and Psychiatry, 2020, 91, 162-171. | 1.9 | 8 |
| 344 | Cortical inexcitability defines an adverse clinical profile in amyotrophic lateral sclerosis. European Journal of Neurology, 2021, 28, 90-97. | 3.3 | 8 |
| 345 | Genetic Analysis of Tryptophan Metabolism Genes in Sporadic Amyotrophic Lateral Sclerosis. Frontiers in Immunology, 2021, 12, 701550. | 4.8 | 8 |
| 346 | Regional differences in ulnar nerve excitability may predispose to the development of entrapment neuropathy. Clinical Neurophysiology, 2011, 122, 194-198. | 1.5 | 7 |
| 347 | The effects of large artery ischemia and subsequent recanalization on nerve excitability. Muscle and Nerve, 2011, 44, 841-841. | 2.2 | 7 |
| 348 | The realm of neurology--past, present and future. Journal of Neurology, Neurosurgery and Psychiatry, 2011, 82, 1-1. | 1.9 | 7 |
| 349 | Amyotrophic lateral sclerosis and frontotemporal dementia. Journal of Neurology, Neurosurgery and Psychiatry, 2012, 83, 355-355. | 1.9 | 7 |
| 350 | Comparative study to evaluate the effects of peritoneal and hemodialysis on peripheral nerve function. Muscle and Nerve, 2016, 54, 58-64. | 2.2 | 7 |
| 351 | Nerve Pathology Distinguishes Focal Motor Chronic Inflammatory Demyelinating Polyradiculoneuropathy From Multifocal Motor Neuropathy. Journal of Clinical Neuromuscular Disease, 2020, 22, 1-10. | 0.7 | 7 |
| 352 | Review Article â€œSpotlight on Ultrasonography in the Diagnosis of Peripheral Nerve Disease: The Evidence to Dateâ€• International Journal of General Medicine, 2021, Volume 14, 4579-4604. | 1.8 | 7 |
| 353 | Problem-focused coping underlying lower caregiver burden in ALS-FTD: implications for caregiver intervention. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2021, 22, 434-441. | 1.7 | 7 |
| 354 | Inflections in threshold electrotonus to depolarizing currents in sensory axons. Muscle and Nerve, 2007, 36, 849-852. | 2.2 | 6 |
| 355 | Immunomodulation of inflammatory leukocyte markers during intravenous immunoglobulin treatment associated with clinical efficacy in chronic inflammatory demyelinating polyradiculoneuropathy. Brain and Behavior, 2016, 6, e00516. | 2.2 | 6 |
| 356 | Emergence of an imaging biomarker for amyotrophic lateral sclerosis: is the end point near?. Journal of Neurology, Neurosurgery and Psychiatry, 2016, 87, 569-569. | 1.9 | 6 |
| 357 | Prognostic factors in C9orf72 amyotrophic lateral sclerosis. Journal of Neurology, Neurosurgery and Psychiatry, 2017, 88, 281.2-281. | 1.9 | 6 |
| 358 | Oxaliplatin and neuropathy: A role for sodium channels. Clinical Neurophysiology, 2018, 129, 670-671. | 1.5 | 6 |
| 359 | Amyotrophic lateral sclerosis: a new diagnostic paradigm. Journal of Neurology, Neurosurgery and Psychiatry, 2020, 91, 903-904. | 1.9 | 6 |
| 360 | Coexisting Lewy body disease and clinical parkinsonism in amyotrophic lateral sclerosis. European Journal of Neurology, 2021, 28, 2192-2199. | 3.3 | 6 |

| # | Article | IF | Citations |
|---|---|---|---|
| 361 | Genetic analysis of GLT8D1 and ARPP21 in Australian familial and sporadic amyotrophic lateral sclerosis. Neurobiology of Aging, 2021, 101, 297.e9-297.e11. | 3.1 | 6 |
| 362 | Brainstem Correlates of Pathological Laughter and Crying Frequency in ALS. Frontiers in Neurology, 2021, 12, 704059. | 2.4 | 6 |
| 363 | Posturography as a biomarker of intravenous immunoglobulin efficacy in chronic inflammatory demyelinating polyradiculoneuropathy. Muscle and Nerve, 2022, 65, 43-50. | 2.2 | 6 |
| 364 | Factors That Influence Non-Motor Impairment Across the ALS-FTD Spectrum: Impact of Phenotype, Sex, Age, Onset and Disease Stage. Frontiers in Neurology, 2021, 12, 743688. | 2.4 | 6 |
| 365 | Neuronal Hyperexcitability and Free Radical Toxicity in Amyotrophic Lateral Sclerosis: Established and Future Targets. Pharmaceuticals, 2022, 15, 433. | 3.8 | 6 |
| 366 | Thalamic and Cerebellar Regional Involvement across the ALSâ€“FTD Spectrum and the Effect of C9orf72. Brain Sciences, 2022, 12, 336. | 2.3 | 6 |
| 367 | Emergence of a Predictive Clinical Biomarker for Diabetic Neuropathy. Diabetes, 2012, 61, 1346-1347. | 0.6 | 5 |
| 368 | Lou Gehrig and the ALS split hand. Neurology, 2015, 85, 1995-1995. | 1.1 | 5 |
| 369 | Progressive bilateral facial weakness. Practical Neurology, 2015, 15, 76-79. | 1.1 | 5 |
| 370 | Sensory and motor axons are different: implications for neurological disease. Annals of Clinical Neurophysiology, 2017, 19, 3. | 0.2 | 5 |
| 371 | Changes in long term peripheral nerve biophysical properties in childhood cancer survivors following neurotoxic chemotherapy. Clinical Neurophysiology, 2020, 131, 783-790. | 1.5 | 5 |
| 372 | Jewels in the crown: a century of achievement for the Journal of Neurology, Neurosurgery & Psychiatry. Journal of Neurology, Neurosurgery and Psychiatry, 2020, 91, 1-2. | 1.9 | 5 |
| 373 | Effect of racial background on motor cortical function as measured by threshold tracking transcranial magnetic stimulation. Journal of Neurophysiology, 2021, 126, 840-844. | 1.8 | 5 |
| 374 | My memories are important to me: Changes in autobiographical memory in amyotrophic lateral sclerosis.. Neuropsychology, 2016, 30, 920-930. | 1.3 | 5 |
| 375 | Kinnier Wilsonâ€™s puzzling features of amyotrophic lateral sclerosis. Journal of Neurology, Neurosurgery and Psychiatry, 2018, 89, 657-666. | 1.9 | 4 |
| 376 | Review of the revised amyotrophic lateral sclerosis diagnostic criteria. Clinical Neurophysiology, 2020, 131, 1767-1768. | 1.5 | 4 |
| 377 | Neural correlates of fat preference in frontotemporal dementia: translating insights from the obesity literature. Annals of Clinical and Translational Neurology, 2021, 8, 1318-1329. | 3.7 | 4 |
| 378 | MiNDAUS partnership: a roadmap for the cure and management of motor Neurone disease. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2022, 23, 321-328. | 1.7 | 4 |

| # | Article | IF | Citations |
|---|---|---|---|
| 379 | A Systematic Review of Caregiver Coping Strategies in Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Journal of Geriatric Psychiatry and Neurology, 2022, 35, 763-777. | 2.3 | 4 |
| 380 | Mitochondrial dysfunction and rod-like lesions associated with administration of Î²2 adrenoceptor agonist formoterol. Neuromuscular Disorders, 2004, 14, 375-377. | 0.6 | 3 |
| 381 | Stimulus, response and excitability â€“ What is new?. Clinical Neurophysiology, 2018, 129, 333-334. | 1.5 | 3 |
| 382 | Fatal cerebellar oedema in adult Leigh syndrome. Practical Neurology, 2020, 20, 336-337. | 1.1 | 3 |
| 383 | Heat sensitivity of sensory fibers in carpal tunnel syndrome. , 1999, 22, 969-970. | | 2 |
| 384 | The contribution of SK3 polymorphisms to acute oxaliplatin-induced neurotoxicity: direct or indirect effects?. Cancer Chemotherapy and Pharmacology, 2011, 67, 1189-1190. | 2.3 | 2 |
| 385 | Acute bulbar, neck and limb weakness with monospecific antiâ€GT1a antibody: A rare localized subtype of Guillainâ€BarrÃ© sydnrome. Muscle and Nerve, 2016, 53, 143-146. | 2.2 | 2 |
| 386 | Some do not like it hot. Journal of Physiology, 2017, 595, 3251-3252. | 2.9 | 2 |
| 387 | Multimodal quantitative examination of nerve function in colorectal cancer patients prior to chemotherapy. Muscle and Nerve, 2018, 57, 615-621. | 2.2 | 2 |
| 388 | Frontostriatal grey matter atrophy in amyotrophic lateral sclerosis A visual rating study. Dementia E Neuropsychologia, 2018, 12, 388-393. | 0.8 | 2 |
| 389 | Patient Editorial Board for JNNP. Journal of Neurology, Neurosurgery and Psychiatry, 2019, 90, 369-370. | 1.9 | 2 |
| 390 | Fasciculation anxiety syndrome in clinicians: FASICS. Practical Neurology, 2020, 20, 433-434. | 1.1 | 2 |
| 391 | Mills Syndrome. Neurology, 2021, 96, 677-678. | 1.1 | 2 |
| 392 | Illness Cognitions in ALS: New Insights Into Clinical Management of Behavioural Symptoms. Frontiers in Neurology, 2021, 12, 740693. | 2.4 | 2 |
| 393 | Nerve biopsy in acquired neuropathies. Journal of the Peripheral Nervous System, 2021, 26 Suppl 2, S21-S41. | 3.1 | 2 |
| 394 | Differences in nerve excitability properties across upper limb sensory and motor axons. Clinical Neurophysiology, 2022, 136, 138-149. | 1.5 | 2 |
| 395 | Development and consensus process for a clinical pathway for the assessment and management of chemotherapy-induced peripheral neuropathy. Supportive Care in Cancer, 2022, 30, 5965-5974. | 2.2 | 2 |
| 396 | A robust framework for characterising diffusion metrics of the median and ulnar nerves: Exploiting stateâ€ofâ€theâ€art tracking methods. Journal of the Peripheral Nervous System, 2022, 27, 67-83. | 3.1 | 2 |

| # | Article | IF | Citations |
|---|---|---|---|
| 397 | Electrodiagnostic findings in facial onset sensory motor neuronopathy (FOSMN). Clinical Neurophysiology, 2022, 140, 228-238. | 1.5 | 2 |
| 398 | Riluzole: a glimmer of hope in the treatment of motor neurone disease. Medical Journal of Australia, 2005, 183, 164-165. | 1.7 | 1 |
| 399 | Why an Australian editor for JNNP?. Journal of Neurology, Neurosurgery and Psychiatry, 2010, 81, 1-1. | 1.9 | 1 |
| 400 | Cortical dysfunction in cerebellar ataxia with antibodies to glutamic acid decarboxylase. Journal of Neurology, 2014, 261, 238-239. | 3.6 | 1 |
| 401 | The Babinski sign. Practical Neurology, 2016, 16, 419-420. | 1.1 | 1 |
| 402 | Author response: Diagnostic criteria in amyotrophic lateral sclerosis: A multicenter prospective study. Neurology, 2017, 88, 719-719. | 1.1 | 1 |
| 403 | Inflammatory neuropathies: all shapes and sizes. Journal of Neurology, Neurosurgery and Psychiatry, 2018, 89, 1128-1128. | 1.9 | 1 |
| 404 | Milestones. Journal of Neurology, Neurosurgery and Psychiatry, 2019, 90, 1189-1189. | 1.9 | 1 |
| 405 | Theme 11 Cognitive and psychological assessment and support. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2019, 20, 301-308. | 1.7 | 1 |
| 406 | Metabolomic insights into neurodegeneÂrative disease. Journal of Neurology, Neurosurgery and Psychiatry, 2020, 91, 1250-1250. | 1.9 | 1 |
| 407 | Treating adults with spinal muscular atrophy with nusinersen. Journal of Neurology, Neurosurgery and Psychiatry, 2020, 91, 1139-1139. | 1.9 | 1 |
| 408 | The Journal of Neurology, Neurosurgery and Psychiatry centenary milestone award 2020. Journal of Neurology, Neurosurgery and Psychiatry, 2020, 91, 677-677. | 1.9 | 1 |
| 409 | Expanding the availability of medications for amyotrophic lateral sclerosis in Australia. Medical Journal of Australia, 2020, 212, 189. | 1.7 | 1 |
| 410 | A novel phenotype of hereditary spastic paraplegia type 7 associated with a compound heterozygous mutation in paraplegin. Muscle and Nerve, 2020, 62, E44-E45. | 2.2 | 1 |
| 411 | Subacute sensory neuronopathy and cancer: the identification of paraneoplastic syndromes. Journal of Neurology, Neurosurgery and Psychiatry, 2020, 91, 793-794. | 1.9 | 1 |
| 412 | Neurology and clinical neurophysiology: an artificial divide. Practical Neurology, 2021, 21, 274-275. | 1.1 | 1 |
| 413 | Clinical evaluation of excitability measures in sensory nerve. Muscle and Nerve, 2001, 24, 883-892. | 2.2 | 1 |
| 414 | Transcranial magnetic stimulation in the cortical exploration of dementia. , 2020, , 327-343. | | 1 |

| # | Article | IF | Citations |
|---|---|---|---|
| 415 | Chapter 23 Pathophysiology of paraesthesiae. Supplements To Clinical Neurophysiology, 2002, 54, 156-162. | 2.1 | 0 |
| 416 | Chemotherapy-Induced Neurotoxicity. , 2010, , 99-119. | | 0 |
| 417 | Response to Karam et al.. Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders, 2012, 13, 159-160. | 2.1 | 0 |
| 418 | Natural history and the dawning of a new era for familial ALS. Journal of Neurology, Neurosurgery and Psychiatry, 2017, 88, 95-96. | 1.9 | 0 |
| 419 | Maternal autoimmunity: risk of neurodevelopmental and neuropsychiatric outcomes. Journal of Neurology, Neurosurgery and Psychiatry, 2017, 88, 713-714. | 1.9 | 0 |
| 420 | Transforming the management of stroke. Medical Journal of Australia, 2017, 206, 342-343. | 1.7 | 0 |
| 421 | Sound of the crowd: wisdom of neurologists revisited. Practical Neurology, 2019, 19, 552-552. | 1.1 | 0 |
| 422 | Motor neuron disease with malignancy: Clinical and pathophysiological insights. Clinical Neurophysiology, 2019, 130, 1557-1561. | 1.5 | 0 |
| 423 | Marco Polo of Australian neurology. Journal of Neurology, Neurosurgery and Psychiatry, 2019, 90, 627-628. | 1.9 | 0 |
| 424 | 009â€…Axonal excitability properties in dravetâ€™s syndrome reflect effect of loss of sodium channels. Journal of Neurology, Neurosurgery and Psychiatry, 2019, 90, A4.1-A4. | 1.9 | 0 |
| 425 | Queen Square: a history of the National Hospital and its Institute of Neurology. Journal of Neurology, Neurosurgery and Psychiatry, 2020, 91, 560-561. | 1.9 | 0 |
| 426 | Neurotoxicity and ALS: Insights into Pathogenesis. , 2021, , 1-19. | | 0 |
| 427 | Author Response: Phenotypic Variability in ALS-FTD and Effect on Survival. Neurology, 2021, 96, 1103-1104. | 1.1 | 0 |
| 428 | 026â€…Posturography as a biomarker of IVIG efficacy in CIDP patients. , 2021, , . | | 0 |
| 429 | The end of the affair?. Journal of Neurology, Neurosurgery and Psychiatry, 2021, 92, 1249-1250. | 1.9 | 0 |
| 430 | Impulse Conduction. , 2003, , 639-642. | | 0 |
| 431 | Neurotoxicity and ALS: Insights into Pathogenesis. , 2014, , 1435-1456. | | 0 |
| 432 | Functional Characterisation of a GWAS Risk Locus Identifies GPX3 as a Lead Candidate Gene in ALS. SSRN Electronic Journal, 0, , . | 0.4 | 0 |

| # | Article | IF | Citations |
|---|---|---|---|
| 433 | Schizotypal traits across the amyotrophic lateral sclerosisâ€“frontotemporal dementia spectrum: pathomechanistic insights. Journal of Neurology, 2022, , 1. | 3.6 | 0 |
| 434 | Brainspotting: Adventures in Neurology. Journal of Neurology, Neurosurgery and Psychiatry, 2022, 93, 800-801. | 1.9 | 0 |